Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Germany (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Anti-Human Lambda FITC/Kappa PE/CD20 PerCP-Cy™5.5

      BD Oncomark™ Anti-Human Lambda FITC/Kappa PE/CD20 PerCP-Cy™5.5

      (RUO (GMP))
      Product Details
      Down Arrow Up Arrow


      BD Oncomark™
      Human
      Flow cytometry
      RUO (GMP)
      Phosphate buffered saline with BSA and 0.1% sodium azide.


      Description

      Anti-Lambda, clone 1-155-2, is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from BALB C/J mice immunized with human IgA1-λ myeloma protein.

      Anti-Kappa, clone TB28-2, is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from CB6 (BC57b x BALB/c) mice immunized with human IgG-κ myeloma protein.

      CD20, clone L27, is derived from hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with the LB lymphoblastoid cell line.

      Anti-Lambda is specific for lambda light chains of human immunoglobulins.

      Anti-Kappa is specific for kappa light chains of human immunoglobulins.

      The CD20 antigen is a phosphoprotein with a molecular weight of 35 or 37 kilodaltons (kd) depending on the degree of phosphorylation. The antigen is not glycosylated.

      Preparation And Storage

      Store vials at 2–8°C. Do not freeze reagents; protect them from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

      Show More blue down arrow Show Less blue up arrow
      346596 Rev. 1
      Components
      Down Arrow Up Arrow
      Description Clone Isotype EntrezGene ID
      Ig, λ Light Chain FITC 1-155-2 IgG1, λ 931
      Ig, κ light chain PE TB28-2 IgG1, κ 931
      CD20 PerCP-Cy™5.5 14D4 IgG2a, κ 12267
      346596 Rev. 1
      Citations & References
      Down Arrow Up Arrow

      Development References (28)

      1. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992; 40:259-263. (Biology).
      2. Almasri NM, Iturraspe JA, Braylan RC. CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles. Arch Pathol Lab Med. 1998; 122:539-544. (Biology).
      3. Braylan RC, Benson NA, Iturraspe J. Analysis of lymphomas by flow cytometry: current and emerging strategies. Ann NY Acad Sci. 1993; 677:364-378. (Biology).
      4. Cabezudo E, Carrara P, Morilla R, Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica. 1999; 84(5):413-418. (Biology).
      5. Chung J, Gong G, Huh J, Khang SK, Ro JY. Flow cytometric immunophenotyping in fine-needle aspiration of lymph nodes. J Korean Med Sci. 1999; 14:393-400. (Biology).
      6. Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E. Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction. Diagn Mol Pathol. 1999; 8:183-188. (Biology).
      7. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Immunol. 1998; 25(1):6-10. (Biology). View Reference
      8. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. KnappW, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York,NY: Oxford University Press; 1989:46-48.
      9. Geary WA, Frierson HF, Innes DJ, Normansell DE. Quantitative criteria for clonality in the diagnosis of B-cell non-Hodgkin's lymphoma by flow cytometry. Mod Pathol. 1993; 6:155-161. (Biology).
      10. Geisler CH, Larsen JK, E HN, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991; 78:1795-1802. (Biology).
      11. Hassan IB, Hagberg H, Sundström C. Immunophenotype of hairy-cell leukemia. Eur J Haematol. 1990; 45:172-176. (Biology).
      12. Hoffkes HG, Schmidtke G, Uppenkamp M, Schmucker U. Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry. Clin Diagn Lab Immunol. 1996; 3:30-36. (Biology).
      13. Huh YO, Pugh WC, Kantarjian HM, et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994; 101:283-289. (Biology).
      14. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on asubpopulation of human T lymphocytes. Cytometry. 1993; 14:196-204. (Biology).
      15. Hübl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry. 1998; 34:71-74. (Biology).
      16. Johnson A, Cavallin-Stahl E, Akerman M. Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Br J Cancer. 1985; 52(2):159-168. (Biology). View Reference
      17. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol . 1996; 105:451-457. (Biology).
      18. Kubagawa H, Gathings WE, Levitt D, Kearney JF, Cooper MD. Immunoglobulin isotype expression of normal pre-B cells as determined by immunofluorescence.. J Clin Immunol. 1982; 2(4):264-9. (Biology). View Reference
      19. Letwin BW, Wallace PK, Muirhead KA, Hensler GL, Kashatus WH, Horan PK. An improved clonal excess assay using flow cytometry and B-cell gating. Blood. 1990; 75:1178-1185. (Biology).
      20. Loken MR, Shah VO, Dattilio K, Civin C. Flow cytometric analysis of human bone marrow, I: Normal erythroid development. Blood. 1987; 69:255-263. (Biology).
      21. Marti GE, Zenger V, Caproaso NE, et al. Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes. Anal Quant Cytol Histol. 1989; 11:315-323. (Biology).
      22. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994; 14:57-61. (Biology).
      23. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994; 8(10):1640-1645. (Biology).
      24. Molot RJ, Meeker TC, Wittwer CT, et al. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas. Blood. 1994; 83:1626-1631. (Biology).
      25. Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998; 110:582-589. (Biology).
      26. Venditti A, Del Poeta G, Stasi R, et al. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows. Haematologica. 1993; 78:359-363. (Biology).
      27. Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma.. Blood. 1984; 63(5):1080-7. (Biology). View Reference
      28. Zardawi IM, Jain S, Bennett G. Flow-cytometric algorithm on fine-needle aspirates for the clinical workup of patients with lymphadenopathy. Diagn Cytopathol. 1998; 19:274-278. (Biology).
      View All (28) View Less
      346596 Rev. 1

      Please refer to Support Documents for Quality Certificates

      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

       

      Although not required, these products are manufactured in accordance with Good Manufacturing Practices.